Julien Lefranc

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking et al. · Molecular Cancer Therapeutics · 2019 · 200 citations

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐<i>c</i>]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

William J. Scott, Martin Hentemann, R. Rowley et al. · ChemMedChem · 2016 · 111 citations · Full text

Nickel‐Catalyzed <i>N</i>‐Arylation of <i>NH</i>‐Sulfoximines with Aryl Halides via Paired Electrolysis

Dong Liu, Zhao‐Ran Liu, Cong Ma et al. · Angewandte Chemie International Edition · 2021 · 96 citations

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Ulrich Lücking, Lars Wortmann, Antje M. Wengner et al. · Journal of Medicinal Chemistry · 2020 · 68 citations · Full text

Tandem β-Alkylation−α-Arylation of Amines by Carbolithiation and Rearrangement of <i>N</i>-Carbamoyl Enamines (Vinyl Ureas)

Jonathan Clayden, Morgan Donnard, Julien Lefranc et al. · Journal of the American Chemical Society · 2010 · 66 citations